Renal Cancer Stem Cells: Characterization and Targeted Therapies by Peired, Anna Julie et al.
Review Article
Renal Cancer Stem Cells: Characterization and
Targeted Therapies
Anna Julie Peired,1,2 Alessandro Sisti,1,3 and Paola Romagnani1,2,3
1Excellence Centre for Research, Transfer and High Education for the Development of DE NOVOTherapies (DENOTHE),
50139 Florence, Italy
2Department of Biomedical, Experimental and Clinical Sciences, University of Florence, 50139 Florence, Italy
3Nephrology Unit, Meyer Children’s University Hospital, 50141 Florence, Italy
Correspondence should be addressed to Anna Julie Peired; anna peired@hotmail.com
Received 17 March 2016; Accepted 24 April 2016
Academic Editor: Ander Abarrategi
Copyright © 2016 Anna Julie Peired et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Renal cell carcinoma (RCC) is a major neoplasm with high incidence in western countries. Tumors are heterogeneous and are
composed of differentiated cancer cells, stromal cells, and cancer stem cells (CSCs). CSCs possess twomain properties: self-renewal
and proliferation. Additionally, they can generate new tumors once transplanted into immunodeficient mice. Several approaches
have been described to identify them, through the expression of cell markers, functional assays, or a combination of both. As CSCs
are involved in the resistance mechanisms to radio- and chemotherapies, several new strategies have been proposed to directly
target CSCs in RCC. One approach drives CSCs to differentiate into cancer cells sensitive to conventional treatments, while the
other proposes to eradicate them selectively. A series of innovative therapies aiming at eliminating CSCs have been designed to
treat other types of cancer and have not been experimented with on RCC yet, but they reveal themselves to be promising. In
conclusion, CSCs are an important player in carcinogenesis and represent a valid target for therapy in RCC patients.
1. Introduction
Renal cell carcinoma (RCC) constitutes the most common
form of renal neoplasms, comprising more than 90% of cases
in adults of both sexes, with an occurrence 2 to 3 times higher
inmen than in women.The incidence increases after 40 years
of age, as for all tumors of epithelial origin, and decreases after
75 years in both sexes [1, 2]. RCC is classified into several
different subtypes based on the pathological features. The
most common subtype is clear cell RCC (ccRCC), followed
by papillary RCC (pRCC), chromophobe, and collecting
duct RCC. The 2013 Vancouver classification includes a total
of 17 morphotypes of renal parenchymal malignancy and
two benign tumors [3–6]. RCC is becoming more com-
monly diagnosed worldwide and, consequently, mortality
is decreasing in the most developed settings. However, it
remains prevalent in low- and middle-income countries,
where access to and the availability of optimal therapies
are likely to be limited [2]. Surgical management of the
primary tumor remains the gold standard of RCC treatment.
Nevertheless, RCC high metastatic index and resistance to
radiation and chemotherapies have led to the development
of new therapeutic agents that target the tumor vasculature
or that attenuate the activation of intracellular oncogenic
pathways [7].
Tumors are heterogeneous structures composed of dif-
ferent types of cancer cells, each cell population presenting
variations in metabolism, receptors, and ligands expression
and epigenetic chromatin structure alterations [8–13]. Iden-
tifying specific cell types within a tumor that either initiate
ormaintain tumorigenesis provides valuable information and
allows a better understanding of tumor biology, as well as
the development of novel treatments. The cell of origin of
cancer, or tumor-initiating cell (TIC), is a normal cell that
sustains mutations leading to tumor formation [14]. The
cells that maintain tumor growth and propagation are the
cancer stem cells (CSCs) [15]. However, the use of the TIC or
CSC terminology is sometimes redundant, as the distinction
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between the two populations is blurry. CSCs possess two
main characteristics: self-renewal and multipotency capacity.
Self-renewal allows unlimited cell division and maintenance
of the stem cell pool in the tumor. Multipotency permits
CSCs to divide and create a progeny that keeps dividing
until they yield terminally differentiated, specialized cells
[16]. Additionally, CSCs can by themselves originate a tumor
mass indefinitely, following transplant into immunodeficient
mice (Figure 1). As amatter of fact, the cancer transplantation
assay constitutes the gold standard in identifying CSCs as it
can provide evidence of both self-renewal and multilineage
potency of CSCs [17]. It consists in implanting a putative
CSC population into immunodeficient mice, and if the cells
give rise to serially transplantable tumors that recapitulate the
cellular heterogeneity of the parental tumors, they can con-
clusively be qualified of CSCs. On the other hand, TICs can
be defined by lineage tracing assays, which allow defining the
cell of origin of transformation inmousemodels [17].The use
of cell-specific promoters allows distinct cell subpopulations
to be labeled, allowing tracking of single-cell-derived clones.
This assay permits us to assess the fate of individual cells that
undergo transformation and form a tumor and to definitively
identify them as TICs. Consecutively, labeled TICs can be
sorted andused in serial transplantation to evaluate their CSC
properties.
Various hypotheses exist to describe the origin of TICs/
CSCs, such as accumulation of several mutations during
their lifespan or reprogramming of tumor cells through ded-
ifferentiation by hypoxia and/or epithelial-to-mesenchymal
transition (EMT) [18–20]. Several mechanisms confer CSCs
resistance to radiation and chemotherapeutic treatments,
including their quiescent state, their presence in hypoxic
microenvironments, upregulation of damage responsemech-
anisms, and their increased drug efflux potential [16, 21].
Conventional therapy does not target the CSC population in
RCC, and despite an initial tumor size reduction the patient
relapses. A better identification and characterization of CSCs
would allow the development of new drugs to selectively
eradicate this population in RCC patients.
2. Cancer Stem Cells in Renal Cell Carcinoma
Renal tubular cells have been extensively described as the
cellular origin of RCC [19]. Numerous studies have attempted
to isolate and characterize a population of CSCs among
tubular cells, using either stem cell markers or functional
assays (Figure 2) [18, 22, 23].
2.1. Stem Cell Markers. Several molecular markers have been
used to identify CSCs and constitute valuable tools for tumor
detection and diagnostic, prognostic, and predictive values,
as well as determination of therapeutic targets [24]. Of note,
nomarker has been found so far that would be expressed only
in CSCs [25].
2.1.1. CD105. CD105, also called endoglin, is a surface
transmembrane molecule that is part of the transforming
growth factor-𝛽 (TGF-𝛽) receptor complex. It regulates
CSC
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CSC
Figure 1: Cancer stem cell model. Tumor cells form a heterogeneous
structure and only the cancer stem cells (CSCs) have the ability to
self-renew and differentiate into different cell types. CSCs can form
new heterogeneous tumors following transplant.
cell proliferation, differentiation, and migration and has an
important role in angiogenesis [26]. In 2008, Bussolati et al.
proposed CD105 as a marker for tumor-initiating stem cells
[27]. Cells from patient specimens of RCC were labeled with
CD105 and separated by magnetic sorting. They represented
less than 10% of the total tumor cells and expressed the
mesenchymal stem cell markers CD44, CD90, CD146, CD73,
and CD29 and the mesodermal marker vimentin (VIM), as
well as the embryonic stem cell markers NANOG, OCT4,
Musashi, and Nestin and embryonic renal marker Pax2, but
lacked differentiative epithelial markers such as Cytokeratin.
These cells were clonogenic and could generate spheres in
specific cell culture medium, which is considered an impor-
tant characteristic of CSCs. They could differentiate in vitro
and in vivo into epithelial cells. CD105+ cells displayed tumor-
initiating activity, and as few as 100 cells could generate
serially transplantable carcinomas in immunodeficient mice
containing few CD105+ tumorigenic cells and a large number
of differentiated CD105− cells. They did not express CD133,
a known marker of adult human tubular progenitor cells
[28, 29]. The same authors also found that extracellular
vesicles (EV) released by renal CD105+ CSCs, but not
EV derived from a more differentiated CD105− tumor cell
population, were able to modify tumor microenvironment
and to promote development of a lung premetastatic niche
[30]. Recently, they further characterized EV and observed
that they favor tumor progression and metastases and are
able to modulate the behavior of monocyte-derived dendritic
cells and impair T-cell immune response by a mechanism
involving HLA-G to the same extent as CSCs [31].
Through automated digital assessment of intratumoral
microvascular density, Dubinski et al. showed that CD105
is an unfavorable prognostic marker in ccRCC [32]. Indeed,
patients with higher CD105 expression level had significantly
shorter progression-free survival as well as a higher tumor
stage. CD105 is an important indicator of clinical outcome
and could become a valuable therapeutic target following
further investigation.
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Figure 2: Identification of cancer stem cells using stem cell markers and functional assays. Several techniques have been described to identify
cancer stem cells (CSCs) and to isolate them by immunomagnetic sorting, flow cytometry, or cell culture. HA: hyaluronic acid; red circle:
Hoechst 33342; blue circle: Rhodamine 123; ALDH: aldehyde dehydrogenase; orange triangle: BODIPY-aminoacetaldehyde (substrate); green
triangle: BODIPY-aminoacetate.
2.1.2. CD133. CD133 is a five-transmembrane domain gly-
coprotein, and its true function still remains elusive [33].
Human CD133 was first isolated from hematopoietic stem
cells by a specific monoclonal antibody that recognized a
specific epitope (clone AC133). CD133 currently serves as a
useful marker for the isolation of many different types of
stem and progenitor cells in adult human tissues, even for
clinical purposes [33]. However, only antibodies recognizing
the epitopes localized in the second extracellular loop, such
as the AC133 and 293C3 clones used to identify human renal
progenitors, are suitable for recognition of stem cells and
progenitor cells, while other antibodies do not specifically
recognize stem cells but also differentiated epithelial cell types
[33]. As previouslymentioned, CD133 is also amarker of renal
progenitor cells in adult human kidney, and resident RCC
CD133+ cells have been shown to promote tumor vascular-
ization and angiogenesis [34]. Bruno et al. sortedCD133+ and
CD133− cells from RCC patients and showed that CD133+
cells alone did not induce tumor formation in immunodefi-
cientmice, but cotransplantedwith cells from theK1 RCC cell
line they led to enhanced development and growth of tumors.
This effect was not imputed to the tumorigenic nature of
CD133+ cells as identical effects were observed using CD133+
cells from normal kidney, and it was speculated that the
CD133+ cells present in the tumor could have migrated from
healthy kidney tissue. Interestingly, the neovasculature was
from human origin, as shown by the presence of humanHLA
class I and CD31, indicating CD133+ cells as their origin,
results corroborated by fluorescence in situ hybridization
for expression of human chromosome X [34]. Galleggiante
et al. identified and characterized a population of ccRCC-
derived CD133+/CD24+ CSCs [35]. Gene expression profile
identified copper transport protein 2 (CTR2) as a mem-
brane marker for this neoplastic population. CTR2 in RCC
patients had an important role in cisplatin-based resistance.
CD133+/CD24+/CTR2+ cells did not express mesenchy-
mal markers and were more undifferentiated than tubular
adult renal progenitor cells. These cells presented in vitro
self-maintenance and differentiating capabilities and could
induce an angiogenic response in vivo. Lindgren et al. isolated
a population of ALDHhigh cells from adult human renal
cortical tissue, which also expressed CD133 and VIM [19, 29].
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They showed that this CD133+/VIM+ population of tubular-
committed progenitors demonstrate a significant transcrip-
tional similarity with pRCC and coexpress VIM, keratin
7 (KRT7), and KRT19, a pattern characteristic of pRCC.
Additionally, VIM+/KRT7+/KRT19+ cells were observed in
cortical adenomata, benign renal neoplasms. These results
suggest that pRCC develops from these progenitor cells and
that cortical adenomas may represent a benign intermediate
step during this oncogenic process.
Clinical significance of CD133 expression in human
RCC is inconsistent and varies greatly between studies [24].
da Costa et al. used an anti-CD133 polyclonal antibody,
which stained diffusely differentiated epithelial structures
in embryonic as well as adult kidneys, and found that
patients in the CD133 low-expression group had a higher
probability of death from RCC and disease progression [36].
Conversely, D’Alterio et al. used an anti-CD133/1 monoclonal
antibody that selectively recognized renal progenitors and
did not see any correlation with the clinical pathological
features or patient prognosis [37]. However, another two
studies which used the anti-CD133 monoclonal antibody
showed contrasting results. Zhang et al. observed that CD133
expression correlated with tumor grade, stage, histological
type, and tumor location [38]. Prognosis of patients with
CD133high, CD44high, positive vasculogenic mimicry, and
low microvessel density was worse than that of patients
with CD133low, CD44low, negative vasculogenic mimicry,
and high microvessel density. Kim et al. reported that high
levels of CD133 expression were observed in ccRCC with
more differentiated morphology and were associated with
a macro-/microcystic pattern, nonsarcomatoid changes, and
nonmetastatic disease and therefore would consider it as a
favorable prognostic marker [39]. A follow-up study by the
same group showed that CD133 may serve as a favorable
prognosticmarker in pRCC, as it correlated with small tumor
size, low Fuhrman nuclear grade, and prolonged disease-
specific survival [40]. Further studies on the significance of
CD133 expression in RCC are thus necessary.
2.1.3. CXCR4. CXCR4 is an alpha-chemokine receptor spe-
cific for stromal-derived factor-1 (SDF-1, also calledCXCL12),
a molecule endowed with potent chemotactic activity.
CXCR4 has been found to be a prognostic marker in various
types of cancer and plays a role in the cell proliferation
and migration of cancer cells [41]. The CXCL12/CXCR4 axis
forms critical communication bridges between tumor cells
and stromal cells to create a permissive microenvironment
for tumor growth and metastasis. Schrader et al. analyzed
CXCL12𝛼/CXCR4 expression and function in human RCC
cell lines (A-498, Caki-1, Caki-2, and HA-7), patient RCC
samples, and corresponding normal kidney tissue [42]. They
observed that none of the four RCC cell lines expressed
CXCL12, while A-498 cells expressed CXCR4. More impor-
tantly, RCC samples showed a decreased expression of
CXCL12 and increased expression of CXCR4, compared to
their respective adjacent normal kidney tissue, revealing a
role in tumor progression. Gassenmaier et al. compared two
RCC cell lines, RCC-26 and RCC-53, in their capacity to
form spheres in vitro and to establish tumors in vivo [43].
They observed differences in levels of chemokine expression,
as CXCR4 was present only in the more tumorigenic cell
line RCC-53. CXCR4+ cells presented CSC characteristics,
such as increased resistance to tyrosine kinase inhibitors,
higher sphere-forming ability, and tumor growth-inducing
potential in vivo, and expressed high levels of stem cell-
associated makers NANOG, OCT3/4, and SOX2. Downreg-
ulation of CXCR4 expression by small interfering RNA or
pharmacological inhibition by AMD3100 hindered sphere
formation and reduced the viability of CXCR4+ cells [43].
Recently, Micucci et al. showed that the enhanced self-
renewal activity of the CXCR4+ spheres was preceded by
the upregulation of hypoxia-inducible factor 2𝛼 (HIF2𝛼) in
the RCC cell lines Caki-1, Caki-2, 786-O, and 769-P [44].
Knockdown of HIF2𝛼 abrogated CXCR4 expression and
sphere formation, while inhibition of HIF2𝛼 abolished tumor
growth in vivo, revealing the crucial role of HIF2𝛼 activation
in CSC expansion.
Numerous studies show that an elevated CXCR4 expres-
sion in tumor samples from RCC patients is correlated with
poor outcome [37, 45–47]. Additionally, CXCR4 is signifi-
cantly related to the biological features of the tumor stage,
including stage, Fuhrman grade, and clinical presentation
[48].
2.1.4. CD44. The CD44 antigen is a cell surface glycopro-
tein involved in cell-cell interactions and cell adhesion and
migration. A major receptor for hyaluronic acid, CD44,
is an extensively described CSC marker in several human
carcinomas [49]. In the human embryonic cell line 293T,
Debeb et al. described CD44+/CD24− cells with several
CSC features [50]. Although the nature of CSCs is still the
subject of debate, CD44+ human carcinomas are highly
malignant and resistant to therapy, and the presence of CD44
has been shown to confer increased metastatic potential,
properties that are frequently associated with CSCs [38, 49].
CD44 is closely associated with proliferation, metastasis,
cancer recurrence, and prognosis in RCC [51]. Lim et al.
suggested that CD44 expression in RCC provides useful
prognostic information both in primary and in metastatic
RCC and may help in determining the appropriate therapy
[51]. A meta-analysis of the literature performed by Li et
al. revealed that elevated CD44 expression is a poor prog-
nostic marker for five-year overall survival and correlates
with high Fuhrman grade and recurrence [52]. A possible
mechanism of upregulation of CD44 expression in ccRCC
has been proposed in 2016 by Ma et al. [53]. They observed
that about a third of tumor samples expressed CD44, with
no correlation with clinical outcome, but associated with
a high density of tumor-associated macrophages. In vitro
experiments using RCC cell lines and human macrophages
demonstrated that CD44 expression increased following
direct coculture with macrophages. Silencing or suppression
by NF-𝜅B inhibitors of TNF-𝛼 onmacrophages abolished the
increased CD44 expression in RCC. This study suggests that
TNF-𝛼 derived from tumor-associatedmacrophages is linked
to CD44 upregulation via NF-𝜅B signaling in ccRCC [53].
Even though the nature of CD44 as CSCmarker is unclear, its
Stem Cells International 5
role in RCC tumorigenicity remains noteworthy and further
investigation might reveal interesting clinical applications.
2.2. Functional Assays. Identifying selective CSCs could be a
difficult task, and several functional assays have been set up
to circumvent this obstacle.
2.2.1. Sphere-Forming Capacity. Zhong et al. proposed to
select CSCs from the SK-RC-42 RCC cell line on their
capacity to form spheres in a serum-free medium, in the
presence of epithelial growth factor and basic fibroblast
growth factor [54]. This cell population expressed stem cell
markers (OCT4, NANOG, BMI, and 𝛽-catenin) and was
more resistant to chemotherapeutic agents and radiation than
monolayer adherent cells. Sphere-forming cells displayed a
distinct immunophenotype, as they did not express MHC-
II, CD80, FAS, and natural killer (NK) activating receptors,
indicating that they could contribute to T-cell and NK cell
immune suppression. Surprisingly, both sphere-forming and
monolayer adherent cells expressed comparable levels of
CD133, CD44, and CD24 markers, while CD105 levels were
higher in monolayer adherent cells [54]. Using the same
approach, Lichner et al. showed that RCC spheres exhibit
CSC properties, including self-renewal, high tumorigenicity,
and differentiation capacity, as well as the expression of
OCT4, NANOG, KLF4, and LIN28 [55]. Interestingly, inhibi-
tion of miR-17 enhanced RCC sphere formation, while over-
expression of miR-17 hampered sphere formation, through
modulation of the TGF-𝛽-EMT axis [55, 56]. miR-17 belongs
to an oncogenic microRNA (miRNA) cluster which is essen-
tial for development and homeostasis [57]. However, the
dual oncogenic/tumor suppressor function of miR-17 and the
other miRNAs of the family has been suggested in various
tumor types, including RCC, and will require close scrutiny
[58, 59]. miRNAs have an important role in posttranscrip-
tional gene regulation and have been shown to be required
for the maintenance of normal pluripotent embryonic stem
cells in mice [60]. They have been described in several other
types of solid tumors, such as breast cancer, and further
investigation of their role in RCC tumor initiation, therapy
resistance, progression, relapse, and metastasis will certainly
help understand tumor biology [61].
2.2.2. Side Population Sorting. Addla et al. isolated CSCs
by sorting the side population (SP) of cells that take up
Hoechst 33342 dye, by flow cytometry analysis [62, 63]. This
technique was previously described to identify hematopoietic
stem cells (HSCs). HSCs can be distinguished by their ability
to form a SP, as they are able to quickly carry out dyes efflux
owing to the presence of specific membrane transporters on
their surface (such as ABC transporters), a property typically
associated with stemness [64]. About 6% of RCC cells could
be defined as SP, and these cells expressed CD105 but not
CD133 and were able to proliferate and differentiate, as well
as grow into spheroids. However, the cells were found to
be both in G0 and in G1 phase of the cell cycle, suggesting
heterogeneity within the SP. Relationship between SP and
CSCs has been questioned in several types of neoplasms,
such as in glioblastoma, where SP does not contribute to
self-renewal and tumorigenicity attributed to CSCs [65, 66].
Huang et al. applied this method to identify SP in five
human RCC cell lines. Flow cytometry analysis revealed that
the 769P cell line contained the largest SP, which presented
CSC characteristics such as the ability to proliferate, self-
renew, and differentiate, as well as strong resistance to
chemotherapy and radiotherapy that could be linked to the
ABCB1 transporter. In vivo serial tumor transplantation in
immunodeficient mice showed that 769P SP cells formed
tumors [67]. Hughes et al. suggested combining Hoechst
SP detection with synchrotron radiation-Fourier transform
infrared spectroscopy in order tomeasure discrete differences
in the biochemistry of small numbers of single cells [68].
They showed that SP cells were very small, consisting of
a nucleus and limited cytoplasm, relative to the remaining
renal cells. A similar SP identification approach consists in
evaluating the cell’s ability to carry out toxins efflux using
Rhodamine 123 (Rho123). Lu et al. separated Rho123high
from Rho123low in the 786-O RCC cell line and showed that
the Rho123high population formed a small subset of cells
with higher proliferative activity, long-term differentiation
potential, resistance to radiation, increased colony-forming
capacity, and high tumorigenicity compared to Rho123low
cells [69]. Rho123high could therefore be considered to be
CSCs, even though they lacked CD105 expression.
Recently, SP cells from the RenCa RCC cell line were
genetically modified to knock out (KO) DnaJ (Hsp40)
homolog, subfamily B, member 8 (Dnajb8) and investigate
its role in the tumorigenicity of RCC [70]. The authors
confirmed a previously described role for this heat shock
protein in the maintenance of RCC CSCs, as Dnajb8 KO
cells showed reduced ratios of SP cells and reduced sphere-
forming capacity [70, 71]. In vivo single-cell transplantation
assay revealed a role for DNAJB8 in tumor initiation, while
in vitro experiments did not indicate a function in stress
responses [70]. SP cells could be used as a potent tool to assess
gene functions in a wide range of experiments. Additionally,
DNAJB8 emerged as a new potential CSC marker. However,
no clinical significance data is available so far for either SP
cells or DNAJB8.
2.2.3. Aldehyde Dehydrogenase 1 Enzymatic Activity. Recent
evidence suggests that enhanced aldehyde dehydrogenase
(ALDH) activity is a hallmark of CSCs, assessable by the
ALDEFLUOR assay [72]. Debeb et al. cultured and passaged
HEK 293T cells as spheres in serum-free stem cell-promoting
medium [50]. They observed a larger number of ALDH+
cells in spheres compared to cells growing in monolayer.
As mentioned earlier, these cells were also CD44+/CD24−
and exhibited a CSC-like phenotype, that is, resistance to
radiation and expression of higher levels of stem cell sur-
vival signaling including 𝛽-catenin, Notch1, and Survivin.
Moreover, spheres have increased expression ofmesenchymal
genes including VIM, N-cadherin, Zeb1, Snail, and Slug as
well as prometastatic genes RhoC, Tenascin C, and MTA1.
Additionally, levels of miRNAs associated with self-renewal
and metastasis formation were significantly decreased in
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the spheres. 293T cells cultured as spheres represent an
important research tool for studying the molecular and bio-
logical mechanisms of CSCs and for testing and developing
new targets for cancer therapy [50]. In ACHN and Caki-
2 RCC cell lines, ALDHhigh cells displayed several CSC
properties in vitro, that is, clonogenic and self-renewal ability
and increased expression of OCT3/4A, NANOG, and Pax2.
ALDHhigh cells had higher tumorigenicity in vivo [73]. Ueda
et al. studied the ALDH enzymatic activity of SP fromACHN
and KRC/Y RCC cell lines [74]. In the metastatic ACHN
cell lines, they observed that ALDH+ cells formed about
15% of the total number of cells and had higher sphere-
forming capacity, self-renewal ability, and tumorigenicity
than ALDH− cells. Furthermore, SP cells were enriched
in ALDH+ cells compared to non-SP cells, suggesting a
certain correlation between ALDH enzymatic activity and
SP. However, in the primary KRC/Y cell line, only 6.5% of
the cells were ALDH+ and this proportion was similar in SP
and non-SP.The population of CD133+/VIM+ cells described
by Lindgren et al. and mentioned earlier were isolated from
ALDHhigh adult human renal cortical tissue, underlining the
importance of combining several isolation techniques [29].
While Ozbek et al. reported that ALDH1 expression was
correlated with tumor grade but not with tumor stage in
patients with RCC, Abourbih et al. observed that ALDH1
expression did not vary significantly based on tumor stage
or grade and did not correlate with progression-free survival
[75, 76]. Further investigations are necessary to determine the
relationship between RCC clinical prognosis and ALDH1.
3. Cancer Stem Cell-Targeted Therapies
As previously stated, tumors from RCC patients show
resistance to chemotherapy and radiation and are weakly
responsive to immunotherapeutic agents such as interferon 𝛼
and interleukin-12. While antiangiogenic drugs like tyrosine
kinase inhibitors (TKI) have significantly improved outcome
in patients with metastatic disease, the majority still presents
resistance over time as the tumor develops evasion mech-
anisms in response to vascular endothelial growth factor
(VEGF) inhibition [77]. Varna et al. have demonstrated the
involvement of CD133+/CXCR4− CSCs in that process [78].
In perinecrotic areas where CSCs were numerous and pre-
dominant, the VEGF inhibitor sunitinib was able to generate
resistance to its own therapeutic effect via induced hypoxia,
which promotes tumor aggressiveness [18]. Indeed, hypoxia
leads to the activation of HIF, which causes adaptive changes
within cancer cells and aggressive behavior contributing to
tumor progression and resistance and conducting to poor
prognosis [44].
Therefore, it might be of great interest to develop new
therapeutic drugs or immunotoxins that target CSCs, based
on molecular mechanisms that regulate stem cell properties
(Figure 3) [16].
3.1. Interleukin-15. The identification of reliable inducers of
CSC differentiation could facilitate the elaboration of efficient
strategies for eradicating CSCs. Azzi et al. demonstrated that
Tumor relapse
Eradication
of CSCs
Differentiation
of CSCs
Tumor
degeneration
Cancer stem cell
Radio- and
chemotherapy
Differentiated cancer cell
Figure 3:Therapies to target radio- and chemoresistant cancer stem
cells. The presence of cancer stem cells (CSCs) in the tumor can
lead to a relapse following conventional therapy. Newly developed
strategies propose to either differentiate or eradicate CSCs, leading
to the degeneration of the tumor.
interleukin-15 (IL-15), a regulator of kidney homeostasis,
could induce the differentiation of CD105+ CSCs from
human RCC [23, 79]. Previously published data on IL-15 and
IL-15R𝛼KOmice showed that IL-15 was an autocrine survival
factor for renal tubular epithelial cells [80, 81]. CD105+ CSCs
treated with IL-15 lost the expression of stem cell markers and
tumor-initiating and sphere-forming ability. On the other
hand, they gained epithelial markers as well as functional
epithelial properties such as polarity and transmembrane
resistance [79]. Most importantly, CD105+ CSCs became
sensitive to the chemotherapeutic drugs vinblastine and
paclitaxel. By contrast, RCC neither secrete the cytokine nor
express—both in vivo and in vitro—the IL-15R𝛾 chain and
JAK3 [82]. Another in vitro study showed that IL-15 upreg-
ulated E-cadherin expression through Υc chain signaling
pathway on renal epithelial tubular cells and blocked their
EMT [83].
A recently completed phase I study recorded on the
National Institutes of Health (NIH) registry (NCT01021059
on https://clinicaltrials.gov/) proposed to administer intra-
venous recombinant human IL-15 in adults with refractory
metastatic malignant melanoma and metastatic renal cell
cancer. Preliminary results showed the safety and feasibility
of the study [84]. IL-15 administration markedly altered the
homeostasis of lymphocyte subsets in blood, in particularNK
cells and 𝛾𝛿 cells and CD8memory T cells. To reduce toxicity
and increase effectiveness of the treatment, dosing strategies
have been modified, including continuous intravenous infu-
sions and subcutaneous IL-15 administration.
3.2. mTOR Inhibitors. The mammalian target of rapamycin
(mTOR) is a serine/threonine protein kinase, member of the
large phosphatidylinositol 3-kinase- (PI3K-) related kinase
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family. It is known to regulate cell growth and cell prolifer-
ation in stem cells [85]. mTOR pathway activation leads to
constitutive HIF-1𝛼 expression, an important signaling in the
pathogenesis of RCC, as well as the expression of cell-cycle
regulators c-myc and cyclin D1 [86–89]. mTOR inhibitors
have been shown to inhibit both tumor cell proliferation
and angiogenesis [90, 91]. Numerous recent studies have
demonstrated the links between the PI3K/Akt/mTOR signal-
ing pathway andCSC biology [92]. Interestingly, experiments
on neuroblastoma showed that rapamycin targets specifically
CSCs [93]. Similar data confirmed that mTOR inhibitors
eradicated CSCs in nasopharyngeal carcinoma, colon cancer,
and pancreatic cancer [94–96]. However, contrasting studies
underline the putative role of CSCs in mTOR inhibitor-
mediated resistance toRCC treatment, in particular in ccRCC
[86]. A recent study detailed this resistance mechanism in
breast cancer [97]. Accumulative evidence shows that mTOR
is an important pathway in carcinogenesis, and a better
understanding of the effects of mTOR inhibition in RCC will
lead to more successful therapies.
On the NIH database, as many as 36 phase I, II, and III
clinical trials, ongoing or completed, propose to use mTOR
inhibitors to treat RCC. The phase III trial on treatment-
resistant patients with metastatic RCC showed safety and
benefits of everolimus over placebo (NCT00410124). Mul-
tiple combination treatments have been proposed to lower
everolimus toxicity while maintaining a sufficient efficiency
[91]. The advantage of such an approach is that it can
modulate different signaling pathways involved in cancer
biology and target both CSCs and cancer cells for a more
global effect.
3.3. Bone Morphogenetic Protein 2. The bone morphogenetic
protein 2 (Bmp-2) encodes a member of the TGF-𝛽 super-
family. It plays an important role in the development of
bone and cartilage, as well as in the regulation of various
cellular processes including cell differentiation, proliferation,
morphogenesis, cellular survival, and apoptosis [98]. BMP-
2 has been reported to either stimulate or inhibit tumor
growth, depending on cancer type [99]. Wang et al. showed
that BMP-2 could inhibit tumorigenicity of CSCs in human
osteosarcoma OS99-1 cells, inhibit tumor growth of human
RCC, and induce bone formation [100–102]. In a follow-up
study, the authors evaluated whether BMP-2 can be used to
block the tumor-initiating ability of human renal ALDH+
CSCs in vitro and induce bone formation in vivo [99]. They
found that BMP-2 inhibited CSC growth, downregulated
the expression of stem cell markers, and upregulated the
transcription of osteogenic markers. ACHN and Caki-2 RCC
cells implanted in immunodeficient mice developed into
large tumors, while animals treated with BMP-2 presented
limited growth and important bone formation, indicating
BMP-2 as a potential new drug targeting CSCs in RCC. A
recent study byMitsui et al. revealed that impaired regulation
of Bmp-2 via epigenetic pathways was associated with RCC
pathogenesis and confirms the usefulness of BMP-2 as a
molecular marker for designing improved diagnostic and
therapeutic strategies for RCC [103]. Several clinical trials
involving BMP-2 treatment have been registered, primarily
for patients with fractured and degenerative disk disease, but
none for cancer patients.
3.4. Other Possible Therapeutic Targets. Numerous other
strategies have been proposed to target CSCs but have
not been experimented with on RCC so far [25, 104,
105]. They include targeting ATP-driven efflux transporters
or cell surface markers, inhibiting CSC-related signaling
pathways, inhibiting autophagy signaling in CSCs, increas-
ing bioavailability of CSC-specific agents, delivering CSC-
specific chemotherapeutics or nucleic acid drugs, and using
CSC-targeted nanocarriers. Among those, a few stand out
and deserve attention.
3.4.1. ATP-Driven Efflux Transporter Inhibition. As previ-
ously stated, CSCs present high levels of ABC transporters,
which might be involved in drug resistance by decreasing
the cellular accumulation of therapeutic agents [106]. Several
groups have attempted to eradicate CSCs using the low
molecular weight inhibitors fumitremorgin C and trypro-
statin or monoclonal antibodies such as cyclosporin A,
VX710, or tariquidar [104, 107, 108]. Their use in clinical
settings has been hindered by low inhibition efficiency and
elevated toxicity to healthy cells.
3.4.2. Cell Surface Marker Inhibition. Monoclonal antibodies
and inhibitors have been proposed to block CSC surface
markers. Jin et al. used an activating antibody directed to
CD44 to inject into immunodeficient mice transplanted
with acute myeloid leukemia and observed lower leukemic
repopulation [104, 109]. Therapies against CD133 have been
successfully used to treat lung cancer, glioblastoma, and liver
cancer [110–112]. Due to the few experiments performed
using this strategy, further studies must be carried out to
validate this approach.
3.4.3. Salinomycin Treatment. Salinomycin is a biologically
active substance isolated from the culture broth of a strain
of Streptomyces albus. Gupta et al. identified salinomycin
as a selective inhibitor of human breast CSCs by high-
throughput screening [113, 114]. Successive studies demon-
strated that salinomycin could kill CSCs in different types
of human cancers including gastric cancer, lung adeno-
carcinoma, osteosarcoma, colorectal cancer, squamous cell
carcinoma, and prostate cancer, most likely by interfering
with ABC drug transporters, the Wnt/𝛽-catenin signaling
pathway, and other CSC pathways. Promising results from
preclinical trials in humanRCC show that salinomycin is able
to effectively eliminate CSCs and to induce partial clinical
regression of heavily pretreated and therapy-resistant cancers
[113, 115].
3.4.4. Nanomedicine-Based Therapies. Recently, nanomedi-
cine-based therapies have been developed to target CSCs
[104]. Nanoparticles can be used as high-capacity carriers for
chemotherapeutic or nucleic acid drugs and can accumulate
at tumor sites through two different mechanisms: a passive
one, that is, enhanced permeation retention due to the higher
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porosity of the vasculature and impaired lymphatic drainage,
or an active one, due to the presence on the nanoparticles
of molecules of high affinity for the receptors exclusively
overexpressed on the surface of CSCs [116, 117]. As an exam-
ple, it has been proposed to incorporate salinomycin into
nanocarriers in order to lower its toxicity. Yao et al. developed
a drug delivery systemwhich targets specifically gastric CSCs
[118]. Indeed, chitosan-coated single wall carbon nanotubes
loaded with salinomycin functionalized with hyaluronic acid
could selectively eliminate CD44+ gastric CSCs in vitro.
As a combination therapy, Zhang et al. used octreotide-
modified paclitaxel-loaded PEG-b-PCL polymeric micelles
and salinomycin-loaded PEG-b-PCL polymeric micelles to
eradicate breast cancer cells [119].While paclitaxel eliminated
the bulk of cancer cells, salinomycin targeted CSCs, resulting
in a stronger antitumoral activity than either drug separately
in vitro and in vivo. Numerous studies in a wide range of
cancers showed the efficiency of nanoparticle-based therapies
to target CSCs [104].
Nanoparticles are becoming a prominent player in the
fight against tumors, asmore than 150 clinical trials registered
with the NIH propose this innovative technology combined
with more conventional therapies to treat cancer.
Despite important progress being made in developing
CSC-targeted therapies, very few discoveries have been trans-
lated to a clinical setting, underlining the complexity of the
mechanisms involved in carcinogenesis. However, the major
mobilization of the scientific community suggests that this
approach is worth exploring notwithstanding the numerous
setbacks.
4. Conclusions
A vast body of evidence supports the existence within
renal tumors of CSCs with self-renewal and multidifferen-
tiation properties. Various approaches have been described
to successfully isolate and characterize CSCs, leading to the
identification of a variety of CSCs and suggesting that several
subpopulations of CSCs may coexist within a heterogeneous
tumor. Combination of stem cell markers with functional
assays permits a better identification of a smaller population
enriched in CSCs, but important limitations have been
observed [22, 120]. For example, functional assays present
important variations in their staining protocols, from dye
concentration to incubation time, leading to important dis-
crepancies in the results [66]. Additionally, culture conditions
as well as cell detachment methods in in vitro experi-
ments must be optimized and standardized in order not to
affect CSC phenotype [121–123]. Despite the aforementioned
caveats, identification of CSCs led to a better understanding
of carcinogenesis.
It is worth noticing that the techniques developed to
isolate and study CSCs are all performed in vitro, eventually
followed by implantation of the cells into immunodeficient
mice to test their tumor forming capacity. However, most
studies involving RCC patient samples failed to verify that
CSCs could be xenografted into immunodeficient mice and
could produce serially transplantable tumors that recapitulate
the original tumoral tissue. Interestingly, Hasmim et al.
proposed an alternative strategy for identifying renal CSCs by
adapting, to in vitro culture, primary cell suspensions from
serial patient-derived xenografts obtained by implanting
RCC samples in immunodeficient mice [124]. They isolated
3 different CSC subsets of cells, which presented different
characteristics and confirmed the heterogeneity of the CSC
population. Indeed, all 3 populations were ALDH+ and
formed serial spheroids but expressed different combinations
of stem cell markers (CD133, CD105, CD146, CD29, OCT4,
NANOG, and Nestin) and the non-CSC tumor marker E-
cadherin. Admirably, all 3 subsets developed serial tumors
in SCID mice and therefore successfully encompassed all
characteristics of CSCs. This approach is gaining attention
within the scientific community, as the use of patient-
derived xenografts will allow in the future the development
of personalized medicine, that is, unique treatment regimens
for individual patients [125].
While their clinical significance remains elusive at the
moment, CSCs undoubtedly play an important role in tumor
resistance to radiotherapy and chemotherapy. To circumvent
this drawback in conventional therapy, several research
groups are taking advantage of CSCs unique properties to
design new drug compounds that selectively target CSCs. A
few therapies, such as IL-15 and mTOR administration, are
already being tested in clinical trials to treat RCC, providing
new prospects for patients.
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